$AKTX +49% 🚀 🔹 Huge move after Akari highlighted ASCO-accepted data for AKTX-101 📈 🔹 Preclinical results show synergy with adagrasib in KRAS-driven pancreat

$AKTX +49% 🚀 🔹 Huge move after Akari highlighted ASCO-accepted data for AKTX-101 📈 🔹 Preclinical results show synergy with adagrasib in KRAS-driven pancreatic cancer models 🔥 🔹 Novel ADC platform uses RNA splicing modulator payloads — a differentiated angle in oncology 💥 🔹 Phase 1 first-in-h…